This article provides a rigorous, evidence-based assessment of the cost-effectiveness of Next-Generation Sequencing (NGS) against traditional single-gene testing methods in chemogenomics and drug development.
Choosing between Next-Generation Sequencing (NGS) and microarrays for chemical perturbation studies is a critical decision that impacts data quality, cost, and biological insights.
This article provides a comprehensive roadmap for researchers and drug development professionals to rigorously validate next-generation sequencing (NGS)-derived chemogenomic signatures.
This article provides a comprehensive comparison of Illumina and Oxford Nanopore Technologies (ONT) sequencing platforms for chemogenomic applications.
This article provides a comprehensive comparison of Next-Generation Sequencing (NGS) and quantitative PCR (qPCR) for gene expression validation in chemogenomics and drug development.
Accurate variant calling is foundational for discovering genetic biomarkers of drug response in chemogenomics.
The integration of next-generation sequencing (NGS) into chemogenomics—the study of how genes influence drug response—generates datasets of immense scale and complexity, creating significant computational bottlenecks.
Next-generation sequencing (NGS) is revolutionizing drug discovery and biomedical research, but its potential is often limited by manual workflow inconsistencies.
This article provides a comprehensive framework for implementing robust quality control (QC) protocols in chemogenomic Next-Generation Sequencing (NGS) workflows.
Next-generation sequencing (NGS) has become indispensable in chemogenomics for uncovering the genetic basis of drug response and toxicity.